

Via Hand Delivery

I HEREBY CERTIFY THAT THIS CORRESPONDENCE WAS HAND-

DELIVERED ON March 27, 2001Alan Sidelin  
Name of Person Hand Delivering Document3.27.2001  
Date

Attorney Docket Number: P32151C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Craig et al.

March 27, 2001

Serial No.: 09/469,902

Group Art Unit No.: 1625

Filed: December 22, 1999

Examiner: C. Chang

For: NOVEL COMPOUND

Assistant Commissioner for Patents  
Washington, D.C. 20231RECEIVED  
MAR 27 1600/2900  
01 MAR 27 PM 1:35SUBSTITUTE AMENDMENTIN RESPONSE TO NOTICE OF NON-COMPLIANCE (37 CFR 1.121)

In response to the Notice of Non-Compliant Amendment (37 CFR 1.121) dated March 16, 2001, having the longer of a one month or 30 day shortened statutory period for response, please enter the following Amendments and Remarks into the record.

Please amend the application as follows.

**Delete all of the pending claims in the application (specifically claims 64 to 113).**

Add claims 114 to 154 as follows.

114. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554, and  $539 \pm 4$  cm<sup>-1</sup>; and/or the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2, and  $31.6 \pm 0.2$  degrees 2 theta.

115. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic